Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 09:07 am Sale | 2024-09-30 | 13G | Pieris Pharmaceuticals, Inc. PIRS | Lynx1 Capital Management LP | 37,436 2.800% | -84,762 (-69.36%) | Filing History |
| 2024-11-14 09:05 am Purchase | 2024-09-30 | 13G | GH Research PLC GHRS | Lynx1 Capital Management LP | 4,195,894 8.100% | 1,201,835 (+40.14%) | Filing History |
| 2024-11-14 09:03 am Sale | 2024-09-30 | 13G | Bionomics Limited BNOX | Lynx1 Capital Management LP | 8,245,095 3.200% | -4,119,480 (-33.32%) | Filing History |
| 2024-11-14 09:01 am Purchase | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | Lynx1 Capital Management LP | 6,880,527 9.900% | 3,746,131 (+119.52%) | Filing History |
| 2024-11-14 09:00 am Purchase | 2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK | Lynx1 Capital Management LP | 5,187,191 9.900% | 2,230,273 (+75.43%) | Filing History |
| 2024-08-09 5:15 pm Purchase | 2024-08-07 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 421,348 13.600% | 179,054 (+73.90%) | Filing History |
| 2024-04-01 7:23 pm Purchase | 2024-03-26 | 13G | iBio, Inc. IBIO | Lynx1 Capital Management LP | 878,492 9.990% | 878,492 (New Position) | Filing History |
| 2024-03-29 4:15 pm Purchase | 2024-03-19 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 242,294 8.700% | 223,336 (+1178.06%) | Filing History |
| 2024-02-16 4:57 pm Purchase | 2024-02-06 | 13G | GH Research PLC GHRS | Lynx1 Capital Management LP | 2,994,059 5.800% | 2,994,059 (New Position) | Filing History |
| 2024-02-14 09:22 am Purchase | 2023-12-31 | 13G | Alpine Immune Sciences, Inc. ALPN | Lynx1 Capital Management LP | 3,813,926 6.600% | 687,753 (+22.00%) | Filing History |
| 2024-02-14 09:21 am Sale | 2023-12-31 | 13G | Kinnate Biopharma Inc. KNTE | Lynx1 Capital Management LP | 1,997,006 4.200% | -216,172 (-9.77%) | Filing History |
| 2024-02-14 09:21 am Sale | 2023-12-31 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 18,958 0.700% | -148,838 (-88.70%) | Filing History |
| 2024-02-14 09:21 am Purchase | 2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC | Lynx1 Capital Management LP | 3,134,396 6.400% | 12,177 (+0.39%) | Filing History |
| 2024-02-14 09:20 am Purchase | 2023-12-31 | 13G | Stoke Therapeutics, Inc. STOK | Lynx1 Capital Management LP | 2,956,918 6.600% | 292,760 (+10.99%) | Filing History |
| 2024-02-14 09:20 am Purchase | 2023-12-31 | 13G | Cabaletta Bio, Inc. CABA | Lynx1 Capital Management LP | 2,139,644 4.990% | 2,139,644 (New Position) | Filing History |
| 2024-02-14 09:19 am Purchase | 2023-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS | Lynx1 Capital Management LP | 122,198 9.900% | 51,841 (+73.68%) | Filing History |
| 2024-02-14 09:19 am Sale | 2023-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Lynx1 Capital Management LP | 46 0.100% | -114,511 (-99.96%) | Filing History |
| 2024-02-14 09:18 am Sale | 2023-12-31 | 13G | Bionomics Limited BNOX | Lynx1 Capital Management LP | 12,364,575 7.800% | -533,400 (-4.14%) | Filing History |
| 2023-11-13 4:55 pm Purchase | 2023-11-01 | 13G | C4 Therapeutics, Inc. CCCC | Lynx1 Capital Management LP | 3,122,219 6.300% | 3,122,219 (New Position) | Filing History |
| 2023-11-06 4:55 pm Purchase | 2023-10-26 | 13G | Stoke Therapeutics, Inc. STOK | Lynx1 Capital Management LP | 2,664,158 6.000% | 2,664,158 (New Position) | Filing History |